Exagen - XGN Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares.
View XGN analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month target prices for Exagen's stock. Their XGN share price forecasts range from $5.00 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 167.5% from the stock's current price.
View analysts price targets for XGN or view top-rated stocks among Wall Street analysts.

Exagen's stock was trading at $2.40 at the beginning of 2023. Since then, XGN stock has increased by 1.3% and is now trading at $2.43.
View the best growth stocks for 2023 here.

Exagen saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 9,700 shares, a decline of 54.9% from the February 28th total of 21,500 shares. Based on an average daily volume of 23,400 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are sold short.
View Exagen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our XGN earnings forecast.

Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.04. The business earned $12.25 million during the quarter, compared to the consensus estimate of $12.13 million. Exagen had a negative net margin of 98.11% and a negative trailing twelve-month return on equity of 70.16%. During the same quarter in the prior year, the company earned ($0.34) earnings per share.

Exagen issued an update on its first quarter 2023 earnings guidance on Tuesday, March, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $9.20 million-$9.70 million, compared to the consensus revenue estimate of $9.33 million.

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

Exagen trades on the NASDAQ under the ticker symbol "XGN."

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XGN stock can currently be purchased for approximately $2.43.

Exagen (NASDAQ:XGN) has a market capitalization of $40.90 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

The company employs 219 workers across the globe.

Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via email at ir@exagen.com.